POTENTIAL TARGETS FROM HUMAN (RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES)1) User may click on the DrReposER ID (the second column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera through AutoDock Vina.

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Seq. Identity (%)	View	Dock
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	8 / 11	LEU A 616 VAL A 624 ALA A 642 TYR A 693 GLY A 697 ASN A 816 LEU A 818 ASP A 829	None	0.70A	36.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1zlt	SERINE/THREONINE-PRO TEIN KINASE CHK1 (Homo sapiens)	8 / 11	LEU A  15 VAL A  23 ALA A  36 TYR A  86 GLY A  90 ASN A 135 LEU A 137 ASP A 148	HYM  A 400 (-4.2A) HYM  A 400 (-4.3A) HYM  A 400 (-3.5A) HYM  A 400 (-4.7A) None HYM  A 400 (-4.2A) HYM  A 400 (-4.5A) HYM  A 400 (-3.9A)	0.56A	26.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	11 / 11	LEU X  17 GLY X  20 VAL X  25 ALA X  37 TYR X  84 MET X  85 GLY X  88 ASN X 135 LEU X 137 ALA X 147 ASP X 148	STU  X 902 (-3.8A) None STU  X 902 ( 4.8A) STU  X 902 (-3.1A) STU  X 902 (-4.6A) None STU  X 902 (-3.5A) STU  X 902 ( 4.9A) STU  X 902 (-4.4A) STU  X 902 ( 4.1A) STU  X 902 (-3.6A)	0.58A	84.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	11 / 11	LEU A 273 GLY A 276 VAL A 281 ALA A 293 TYR A 340 MET A 341 GLY A 344 ASN A 391 LEU A 393 ALA A 403 ASP A 404	H8H  A 534 (-3.8A) None H8H  A 534 (-4.4A) H8H  A 534 (-3.2A) H8H  A 534 (-4.3A) None H8H  A 534 (-3.3A) H8H  A 534 ( 4.9A) H8H  A 534 (-4.5A) H8H  A 534 ( 4.0A) H8H  A 534 (-4.2A)	0.67A	52.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	9 / 11	LEU A 273 GLY A 276 VAL A 281 ALA A 293 MET A 341 GLY A 344 ASN A 391 LEU A 393 ALA A 403	QUE  A   1 (-3.9A) None QUE  A   1 ( 4.8A) QUE  A   1 (-3.5A) None QUE  A   1 (-3.0A) None QUE  A   1 (-4.4A) QUE  A   1 ( 4.5A)	0.64A	51.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	9 / 11	LEU A 273 GLY A 279 VAL A 281 ALA A 293 MET A 341 GLY A 344 ASN A 391 LEU A 393 ALA A 403	QUE  A   1 (-3.9A) None QUE  A   1 ( 4.8A) QUE  A   1 (-3.5A) None QUE  A   1 (-3.0A) None QUE  A   1 (-4.4A) QUE  A   1 ( 4.5A)	1.16A	51.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	9 / 11	LEU A 251 VAL A 259 ALA A 271 MET A 319 GLY A 322 ASN A 369 LEU A 371 ALA A 381 ASP A 382	1BM  A 499 ( 3.7A) 1BM  A 499 ( 4.8A) 1BM  A 499 (-3.6A) None 1BM  A 499 (-3.5A) 1BM  A 499 (-4.1A) 1BM  A 499 (-4.4A) 1BM  A 499 ( 3.7A) 1BM  A 499 (-4.4A)	0.50A	67.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	9 / 11	LEU A 248 GLY A 251 VAL A 256 ALA A 269 MET A 318 GLY A 321 LEU A 370 ALA A 380 ASP A 381	GIN  A 600 ( 4.6A) None GIN  A 600 ( 4.7A) GIN  A 600 (-3.1A) None None GIN  A 600 (-4.7A) GIN  A 600 (-3.1A) GIN  A 600 (-4.9A)	0.77A	48.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2i0e	PROTEIN KINASE C-BETA II (Homo sapiens)	8 / 11	LEU A 348 GLY A 351 VAL A 356 ALA A 369 TYR A 422 ASN A 471 ALA A 483 ASP A 484	PDS  A 901 (-3.9A) None PDS  A 901 (-4.2A) PDS  A 901 (-3.3A) PDS  A 901 (-4.7A) PDS  A 901 (-4.3A) PDS  A 901 (-3.4A) PDS  A 901 (-3.6A)	0.70A	25.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	8 / 11	LEU A 588 VAL A 596 ALA A 614 TYR A 665 GLY A 669 ASN A 783 LEU A 785 ASP A 796	None	0.56A	34.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2psq	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	9 / 11	LEU A 487 GLY A 493 VAL A 495 ALA A 515 TYR A 566 GLY A 570 ASN A 631 LEU A 633 ALA A 643	None	0.85A	32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2r2p	EPHRIN TYPE-A RECEPTOR 5 (Homo sapiens)	8 / 11	VAL A 689 ALA A 705 TYR A 755 MET A 756 GLY A 759 ASN A 805 LEU A 807 ASP A 818	None	0.53A	43.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2v55	RHO-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	10 / 11	GLY A  85 VAL A  90 ALA A 103 TYR A 155 MET A 156 GLY A 159 ASN A 203 LEU A 205 ALA A 215 ASP A 216	ANP  A1480 ( 3.8A) None ANP  A1480 ( 3.9A) ANP  A1480 ( 4.9A) None None MG  A1481 (-3.5A) ANP  A1480 ( 4.7A) ANP  A1480 ( 4.1A) ANP  A1480 (-3.5A)	0.72A	23.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2vd5	DMPK PROTEIN (Homo sapiens)	8 / 11	GLY A  80 VAL A  85 ALA A  98 TYR A 150 ASN A 200 LEU A 202 ALA A 212 ASP A 213	None BI8  A1417 ( 4.7A) BI8  A1417 ( 3.8A) BI8  A1417 (-4.8A) BI8  A1417 (-3.6A) BI8  A1417 (-4.8A) BI8  A1417 ( 4.1A) BI8  A1417 (-3.8A)	0.62A	25.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2xik	SERINE/THREONINE PROTEIN KINASE 25 (Homo sapiens)	8 / 11	VAL A  34 ALA A  47 TYR A  97 GLY A 101 ASN A 145 LEU A 147 ALA A 157 ASP A 158	J60  A1294 ( 4.9A) J60  A1294 (-3.3A) J60  A1294 (-4.5A) J60  A1294 ( 3.8A) None J60  A1294 (-4.8A) J60  A1294 ( 4.2A) J60  A1294 ( 4.6A)	0.49A	29.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2xk9	CHECKPOINT KINASE 2 (Homo sapiens)	8 / 11	LEU A 226 GLY A 229 VAL A 234 ALA A 247 MET A 304 GLY A 307 ASN A 352 LEU A 354	XK9  A1511 (-3.8A) None XK9  A1511 (-4.8A) XK9  A1511 ( 4.1A) None XK9  A1511 ( 3.7A) None XK9  A1511 (-4.6A)	0.70A	28.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3b2t	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	9 / 11	LEU A 487 GLY A 490 VAL A 495 ALA A 515 TYR A 566 GLY A 570 ASN A 631 LEU A 633 ALA A 643	M33  A1996 (-4.0A) M33  A1996 (-3.0A) M33  A1996 ( 4.7A) M33  A1996 (-3.3A) M33  A1996 ( 4.7A) M33  A1996 ( 4.8A) None M33  A1996 (-4.5A) None	0.45A	36.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3c4f	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	8 / 11	LEU A 484 VAL A 492 ALA A 512 TYR A 563 GLY A 567 ASN A 628 LEU A 630 ALA A 640	C4F  A   1 ( 3.9A) None C4F  A   1 (-3.3A) None None None C4F  A   1 (-4.6A) C4F  A   1 (-3.6A)	0.65A	36.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	9 / 11	GLY A 204 VAL A 209 ALA A 220 TYR A 268 MET A 269 GLY A 272 ASN A 319 LEU A 321 ASP A 332	None	0.41A	42.01
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	9 / 11	GLY A 207 VAL A 209 ALA A 220 TYR A 268 MET A 269 GLY A 272 ASN A 319 LEU A 321 ASP A 332	None	1.02A	42.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3iec	SERINE/THREONINE-PRO TEIN KINASE MARK2 (Homo sapiens)	8 / 11	VAL A  67 ALA A  80 TYR A 131 GLY A 135 ASN A 180 LEU A 182 ALA A 192 ASP A 193	None	0.74A	27.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3kul	EPHRIN TYPE-A RECEPTOR 8 (Homo sapiens)	8 / 11	VAL A 649 ALA A 665 TYR A 715 MET A 716 GLY A 719 ASN A 765 LEU A 767 ASP A 778	None None GOL  A 403 (-4.1A) None GOL  A 403 (-3.4A) None None None	0.68A	38.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3lm5	SERINE/THREONINE-PRO TEIN KINASE 17B (Homo sapiens)	8 / 11	LEU A  39 GLY A  42 VAL A  47 ALA A  60 TYR A 112 GLY A 116 ASN A 163 LEU A 165	QUE  A   1 ( 3.8A) None QUE  A   1 ( 4.6A) QUE  A   1 (-3.2A) QUE  A   1 (-4.9A) None None None	0.74A	27.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3mvj	CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA (Homo sapiens)	9 / 11	LEU A  49 GLY A  52 VAL A  57 ALA A  70 TYR A 122 GLY A 126 ASN A 171 LEU A 173 ASP A 184	XFE  A 351 (-4.2A) None XFE  A 351 ( 4.5A) XFE  A 351 (-3.2A) None None None XFE  A 351 (-4.6A) None	0.86A	23.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3my0	SERINE/THREONINE-PRO TEIN KINASE RECEPTOR R3 (Homo sapiens)	8 / 11	VAL A 216 ALA A 227 TYR A 279 GLY A 283 ASN A 335 LEU A 337 ALA A 347 ASP A 348	LDN  A 600 (-4.5A) LDN  A 600 (-3.2A) LDN  A 600 (-4.7A) LDN  A 600 (-3.3A) LDN  A 600 (-4.5A) LDN  A 600 (-4.6A) LDN  A 600 ( 3.8A) None	0.72A	27.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3nuu	PKB-LIKE (Homo sapiens)	9 / 11	LEU A  88 GLY A  91 VAL A  96 ALA A 109 TYR A 161 GLY A 165 ASN A 210 LEU A 212 ASP A 223	JOZ  A 361 (-4.1A) SO4  A   5 ( 4.4A) JOZ  A 361 ( 4.7A) JOZ  A 361 (-3.4A) None None None None SO4  A   5 ( 4.5A)	0.77A	26.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3nyo	G PROTEIN-COUPLED RECEPTOR KINASE 6 (Homo sapiens)	8 / 11	LEU A 192 VAL A 200 ALA A 213 MET A 266 GLY A 269 ASN A 316 LEU A 318 ASP A 329	AMP  A 577 ( 4.3A) AMP  A 577 (-4.3A) AMP  A 577 (-3.4A) None None AMP  A 577 (-4.2A) AMP  A 577 (-4.8A) AMP  A 577 (-4.0A)	0.50A	22.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3pls	MACROPHAGE-STIMULATI NG PROTEIN RECEPTOR (Homo sapiens)	8 / 11	GLY A1091 VAL A1096 ALA A1112 TYR A1163 MET A1164 GLY A1167 ASN A1213 ALA A1225	ANP  A1358 (-3.4A) ANP  A1358 (-4.4A) ANP  A1358 ( 3.8A) ANP  A1358 (-4.3A) None None MG  A   1 ( 2.9A) None	0.67A	37.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3tt0	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	9 / 11	LEU A 484 GLY A 487 VAL A 492 ALA A 512 TYR A 563 GLY A 567 ASN A 628 LEU A 630 ALA A 640	07J  A   1 ( 4.3A) None 07J  A   1 (-4.0A) 07J  A   1 (-3.5A) 07J  A   1 (-4.7A) 07J  A   1 (-3.7A) None 07J  A   1 ( 4.4A) 07J  A   1 (-3.2A)	0.75A	33.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3txo	PROTEIN KINASE C ETA TYPE (Homo sapiens)	8 / 11	LEU A 361 GLY A 364 VAL A 369 ALA A 382 ASN A 484 LEU A 486 ALA A 496 ASP A 497	07U  A   1 ( 4.8A) None 07U  A   1 (-4.8A) 07U  A   1 (-3.3A) None 07U  A   1 (-4.3A) 07U  A   1 ( 4.0A) 07U  A   1 (-3.6A)	0.71A	24.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3v5q	NT-3 GROWTH FACTOR RECEPTOR (Homo sapiens)	8 / 11	LEU A 544 VAL A 552 ALA A 570 TYR A 619 MET A 620 GLY A 623 ASN A 684 LEU A 686	0F4  A 902 ( 4.2A) None 0F4  A 902 (-3.2A) 0F4  A 902 (-4.2A) None 0F4  A 902 (-3.4A) None 0F4  A 902 (-4.5A)	0.50A	34.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3w18	AURORA KINASE A (Homo sapiens)	8 / 11	LEU A 139 GLY A 142 VAL A 147 ALA A 160 TYR A 212 ASN A 261 LEU A 263 ALA A 273	N13  A 501 (-3.7A) None N13  A 501 ( 4.7A) N13  A 501 ( 4.1A) N13  A 501 (-4.4A) None N13  A 501 (-4.5A) N13  A 501 ( 3.8A)	0.57A	24.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3w18	AURORA KINASE A (Homo sapiens)	8 / 11	LEU A 139 VAL A 147 ALA A 160 TYR A 212 GLY A 216 ASN A 261 LEU A 263 ALA A 273	N13  A 501 (-3.7A) N13  A 501 ( 4.7A) N13  A 501 ( 4.1A) N13  A 501 (-4.4A) N13  A 501 (-3.5A) None N13  A 501 (-4.5A) N13  A 501 ( 3.8A)	0.59A	24.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	8 / 11	LEU A  75 GLY A  78 VAL A  83 ALA A  96 MET A 147 GLY A 150 ASN A 196 LEU A 198	ANP  A 401 (-3.8A) ANP  A 401 (-3.3A) ANP  A 401 ( 4.3A) ANP  A 401 (-3.2A) None ANP  A 401 ( 4.3A) MG  A 402 ( 2.9A) ANP  A 401 (-4.8A)	0.74A	27.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	8 / 11	LEU A1951 VAL A1959 ALA A1978 MET A2029 GLY A2032 ASN A2084 LEU A2086 ASP A2102	VGH  A3000 ( 4.4A) None VGH  A3000 (-3.4A) None VGH  A3000 (-3.5A) None VGH  A3000 (-4.3A) None	0.65A	40.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4af3	AURORA KINASE B (Homo sapiens)	8 / 11	LEU A  83 VAL A  91 ALA A 104 TYR A 156 GLY A 160 ASN A 205 LEU A 207 ALA A 217	VX6  A 500 (-3.8A) VX6  A 500 ( 4.8A) VX6  A 500 (-3.4A) VX6  A 500 (-4.2A) VX6  A 500 (-3.3A) None VX6  A 500 (-4.6A) VX6  A 500 ( 4.2A)	0.64A	23.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4at3	BDNF/NT-3 GROWTH FACTORS RECEPTOR (Homo sapiens)	9 / 11	LEU A 560 VAL A 568 ALA A 586 TYR A 635 MET A 636 GLY A 639 ASN A 697 LEU A 699 ASP A 710	LTI  A1839 ( 4.2A) None LTI  A1839 (-3.3A) LTI  A1839 (-4.7A) None LTI  A1839 (-3.4A) None LTI  A1839 (-4.2A) None	0.60A	33.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4c02	ACTIVIN RECEPTOR TYPE-1 (Homo sapiens)	8 / 11	GLY A 217 VAL A 222 ALA A 233 TYR A 285 GLY A 289 ASN A 341 LEU A 343 ALA A 353	None TAK  A1507 (-4.7A) TAK  A1507 (-3.3A) TAK  A1507 ( 4.6A) TAK  A1507 (-3.5A) None TAK  A1507 (-4.7A) TAK  A1507 ( 4.2A)	0.69A	28.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4crs	SERINE/THREONINE-PRO TEIN KINASE N2 (Homo sapiens)	8 / 11	LEU A 663 GLY A 666 VAL A 671 ALA A 684 TYR A 739 GLY A 743 LEU A 789 ASP A 800	AGS  A1985 (-4.2A) AGS  A1985 (-2.9A) AGS  A1985 (-4.6A) AGS  A1985 (-3.5A) None None AGS  A1985 (-4.8A) AGS  A1985 ( 3.3A)	0.70A	24.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4crs	SERINE/THREONINE-PRO TEIN KINASE N2 (Homo sapiens)	9 / 11	LEU A 663 VAL A 671 ALA A 684 TYR A 739 GLY A 743 ASN A 787 LEU A 789 ALA A 799 ASP A 800	AGS  A1985 (-4.2A) AGS  A1985 (-4.6A) AGS  A1985 (-3.5A) None None MG  A1986 ( 3.2A) AGS  A1985 (-4.8A) AGS  A1985 ( 4.5A) AGS  A1985 ( 3.3A)	0.56A	24.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4f0i	HIGH AFFINITY NERVE GROWTH FACTOR RECEPTOR (Homo sapiens)	9 / 11	LEU A 515 VAL A 523 ALA A 541 TYR A 590 MET A 591 GLY A 594 ASN A 654 LEU A 656 ASP A 667	None	0.77A	33.98
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4fod	ALK TYROSINE KINASE RECEPTOR (Homo sapiens)	8 / 11	LEU A1122 VAL A1130 ALA A1148 MET A1199 GLY A1202 ASN A1254 LEU A1256 ASP A1270	0UV  A1501 (-3.8A) 0UV  A1501 (-4.5A) 0UV  A1501 (-3.4A) None 0UV  A1501 (-3.6A) 0UV  A1501 ( 4.9A) 0UV  A1501 (-4.6A) 0UV  A1501 ( 4.2A)	0.48A	33.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4hvi	TYROSINE-PROTEIN KINASE JAK3 (Homo sapiens)	10 / 11	LEU A 828 GLY A 831 VAL A 836 ALA A 853 TYR A 904 GLY A 908 ASN A 954 LEU A 956 ALA A 966 ASP A 967	19S  A1201 (-3.9A) 19S  A1201 ( 4.3A) 19S  A1201 (-4.4A) 19S  A1201 (-3.3A) 19S  A1201 (-4.7A) 19S  A1201 ( 3.8A) None 19S  A1201 (-4.5A) 19S  A1201 ( 4.1A) 19S  A1201 ( 4.1A)	0.73A	33.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4hvi	TYROSINE-PROTEIN KINASE JAK3 (Homo sapiens)	9 / 11	LEU A 828 GLY A 834 VAL A 836 ALA A 853 TYR A 904 ASN A 954 LEU A 956 ALA A 966 ASP A 967	19S  A1201 (-3.9A) 19S  A1201 ( 4.9A) 19S  A1201 (-4.4A) 19S  A1201 (-3.3A) 19S  A1201 (-4.7A) None 19S  A1201 (-4.5A) 19S  A1201 ( 4.1A) 19S  A1201 ( 4.1A)	1.25A	33.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4id7	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	8 / 11	LEU A 132 GLY A 135 VAL A 140 ALA A 156 GLY A 211 ASN A 257 LEU A 259 ASP A 270	1G0  A 401 ( 4.5A) None 1G0  A 401 (-4.4A) 1G0  A 401 (-3.6A) 1G0  A 401 ( 4.5A) None 1G0  A 401 (-4.6A) None	0.67A	39.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4k11	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	10 / 11	LEU A 273 GLY A 276 VAL A 281 ALA A 293 TYR A 340 MET A 341 GLY A 344 ASN A 391 LEU A 393 ALA A 403	0J9  A 601 (-4.0A) None 0J9  A 601 (-4.4A) 0J9  A 601 (-3.3A) 0J9  A 601 ( 4.7A) None 0J9  A 601 ( 4.1A) None 0J9  A 601 (-4.5A) 0J9  A 601 (-3.5A)	0.49A	94.59
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4k11	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	9 / 11	LEU A 273 GLY A 279 VAL A 281 ALA A 293 TYR A 340 MET A 341 ASN A 391 LEU A 393 ALA A 403	0J9  A 601 (-4.0A) None 0J9  A 601 (-4.4A) 0J9  A 601 (-3.3A) 0J9  A 601 ( 4.7A) None None 0J9  A 601 (-4.5A) 0J9  A 601 (-3.5A)	1.03A	94.59
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	10 / 11	LEU A 478 GLY A 481 VAL A 486 ALA A 506 TYR A 557 GLY A 561 ASN A 622 LEU A 624 ALA A 634 ASP A 635	ACP  A 801 (-3.8A) ACP  A 801 (-3.6A) ACP  A 801 (-4.2A) ACP  A 801 (-3.3A) None ACP  A 801 ( 4.6A) MG  A 802 ( 2.4A) ACP  A 801 (-4.4A) None MG  A 802 ( 3.0A)	0.60A	35.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	10 / 11	LEU A 478 GLY A 484 VAL A 486 ALA A 506 TYR A 557 GLY A 561 ASN A 622 LEU A 624 ALA A 634 ASP A 635	ACP  A 801 (-3.8A) ACP  A 801 (-3.6A) ACP  A 801 (-4.2A) ACP  A 801 (-3.3A) None ACP  A 801 ( 4.6A) MG  A 802 ( 2.4A) ACP  A 801 (-4.4A) None MG  A 802 ( 3.0A)	0.86A	35.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4o27	SERINE/THREONINE-PRO TEIN KINASE 24 (Homo sapiens)	9 / 11	GLY B  33 VAL B  38 ALA B  51 TYR B 101 GLY B 105 ASN B 149 LEU B 151 ALA B 161 ASP B 162	ADP  B 500 (-3.3A) ADP  B 500 (-4.5A) ADP  B 500 (-3.3A) ADP  B 500 ( 4.7A) None MN  B 501 ( 3.1A) ADP  B 500 (-4.7A) None ADP  B 500 ( 3.4A)	0.60A	30.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4otd	SERINE/THREONINE-PRO TEIN KINASE N1 (Homo sapiens)	10 / 11	LEU A 627 GLY A 630 VAL A 635 ALA A 648 TYR A 703 GLY A 707 ASN A 751 LEU A 753 ALA A 763 ASP A 764	None	0.89A	26.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4q9z	HUMAN PROTEIN KINASE C THETA (Homo sapiens)	8 / 11	LEU A 386 GLY A 389 VAL A 394 ALA A 407 TYR A 460 ASN A 509 LEU A 511 ALA A 521	PZW  A 801 (-3.9A) None PZW  A 801 (-4.6A) PZW  A 801 (-3.5A) None PZW  A 801 (-4.4A) PZW  A 801 (-4.8A) PZW  A 801 ( 4.6A)	0.54A	24.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4rt7	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	8 / 11	LEU A 616 VAL A 624 ALA A 642 TYR A 693 GLY A 697 ASN A 816 LEU A 818 ASP A 829	P30  A1001 (-3.8A) None P30  A1001 (-3.4A) P30  A1001 (-4.1A) P30  A1001 (-3.4A) None P30  A1001 (-4.6A) None	0.66A	32.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4wb7	DNAJ HOMOLOG SUBFAMILY B MEMBER 1,CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA (Homo sapiens)	8 / 11	LEU A 104 GLY A 107 VAL A 112 ALA A 125 TYR A 177 GLY A 181 LEU A 228 ASP A 239	ATP  A 501 ( 4.3A) ATP  A 501 (-3.2A) ATP  A 501 (-4.0A) ATP  A 501 (-3.4A) None None ATP  A 501 (-4.5A) ZN  A 503 (-1.9A)	0.75A	23.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4wb7	DNAJ HOMOLOG SUBFAMILY B MEMBER 1,CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA (Homo sapiens)	8 / 11	LEU A 104 VAL A 112 ALA A 125 TYR A 177 GLY A 181 ASN A 226 LEU A 228 ASP A 239	ATP  A 501 ( 4.3A) ATP  A 501 (-4.0A) ATP  A 501 (-3.4A) None None ZN  A 502 ( 2.5A) ATP  A 501 (-4.5A) ZN  A 503 (-1.9A)	0.69A	23.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4wsq	AP2-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	8 / 11	LEU A  52 GLY A  55 VAL A  60 ALA A  72 GLY A 132 ASN A 181 LEU A 183 ASP A 194	KSA  A 405 ( 4.0A) KSA  A 405 ( 4.9A) KSA  A 405 ( 4.9A) KSA  A 405 (-3.2A) KSA  A 405 (-3.5A) KSA  A 405 (-4.0A) KSA  A 405 (-4.6A) ZN  A 403 ( 2.6A)	0.71A	26.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	8 / 11	LEU B 267 VAL B 275 ALA B 288 MET B 337 GLY B 340 ASN B 387 LEU B 389 ALA B 399	1N1  B 601 (-3.7A) 1N1  B 601 ( 4.9A) 1N1  B 601 (-3.5A) None 1N1  B 601 (-3.5A) None 1N1  B 601 (-4.3A) 1N1  B 601 (-3.5A)	0.53A	36.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xuf	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	8 / 11	LEU A 616 GLY A 619 VAL A 624 ALA A 642 TYR A 693 GLY A 697 ASN A 816 LEU A 818	P30  A1001 (-4.0A) None P30  A1001 ( 4.8A) P30  A1001 (-3.5A) P30  A1001 ( 4.4A) P30  A1001 (-3.5A) None P30  A1001 (-4.3A)	0.64A	38.01
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5a46	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B (Homo sapiens)	8 / 11	LEU A 484 VAL A 492 ALA A 512 TYR A 563 GLY A 567 ASN A 628 LEU A 630 ALA A 640	38O  A1769 (-3.2A) 38O  A1769 (-4.5A) 38O  A1769 (-3.6A) 38O  A1769 (-4.2A) 38O  A1769 (-3.4A) None 38O  A1769 (-4.6A) EDO  A1766 ( 4.4A)	0.49A	32.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5ci7	SERINE/THREONINE-PRO TEIN KINASE ULK1 (Homo sapiens)	8 / 11	GLY A  25 VAL A  30 ALA A  44 TYR A  94 GLY A  98 ASN A 143 LEU A 145 ALA A 164	GOL  A 404 ( 3.2A) 51W  A 401 ( 4.3A) 51W  A 401 (-3.4A) 51W  A 401 ( 3.4A) 51W  A 401 (-3.7A) GOL  A 404 ( 4.6A) 51W  A 401 (-4.5A) None	0.57A	27.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5es1	MAP/MICROTUBULE AFFINITY-REGULATING KINASE 4 (Homo sapiens)	9 / 11	GLY A  65 VAL A  70 ALA A  83 TYR A 134 GLY A 138 ASN A 183 LEU A 185 ALA A 195 ASP A 196	5RC  A4000 ( 3.9A) 5RC  A4000 (-4.6A) 5RC  A4000 (-3.6A) 5RC  A4000 (-4.5A) 5RC  A4000 (-3.3A) 5RC  A4000 (-4.1A) None 5RC  A4000 ( 3.9A) 5RC  A4000 (-3.6A)	0.85A	29.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5fm2	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET (Homo sapiens)	8 / 11	LEU A 730 GLY A 733 VAL A 738 ALA A 756 TYR A 806 GLY A 810 ASN A 879 LEU A 881	PP1  A2012 (-4.6A) None PP1  A2012 (-4.4A) PP1  A2012 (-3.2A) None PTR  A 809 (-2.4A) None PP1  A2012 (-4.6A)	0.62A	31.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5i3o	BMP-2-INDUCIBLE PROTEIN KINASE (Homo sapiens)	8 / 11	LEU A  57 GLY A  60 VAL A  65 ALA A  77 TYR A 132 GLY A 136 LEU A 187 ASP A 198	IDV  A 401 (-3.8A) IDV  A 401 (-3.5A) IDV  A 401 (-4.6A) IDV  A 401 (-3.6A) IDV  A 401 (-3.5A) IDV  A 401 (-3.4A) IDV  A 401 (-4.4A) IDV  A 401 (-4.0A)	0.75A	25.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5i3o	BMP-2-INDUCIBLE PROTEIN KINASE (Homo sapiens)	8 / 11	LEU A  57 VAL A  65 ALA A  77 TYR A 132 GLY A 136 ASN A 185 LEU A 187 ASP A 198	IDV  A 401 (-3.8A) IDV  A 401 (-4.6A) IDV  A 401 (-3.6A) IDV  A 401 (-3.5A) IDV  A 401 (-3.4A) IDV  A 401 (-4.1A) IDV  A 401 (-4.4A) IDV  A 401 (-4.0A)	0.76A	25.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5iso	5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-2 (Homo sapiens)	9 / 11	LEU A  22 VAL A  30 ALA A  43 TYR A  95 GLY A  99 ASN A 144 LEU A 146 ALA A 156 ASP A 157	STU  A 601 (-4.1A) STU  A 601 (-4.8A) STU  A 601 (-3.3A) STU  A 601 (-4.3A) STU  A 601 ( 4.0A) STU  A 601 (-4.3A) STU  A 601 (-4.5A) STU  A 601 (-3.5A) STU  A 601 (-3.5A)	0.95A	22.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5kbr	SERINE/THREONINE-PRO TEIN KINASE PAK 1 (Homo sapiens)	8 / 11	GLY A 279 VAL A 284 ALA A 297 TYR A 346 GLY A 350 ASN A 394 LEU A 396 ASP A 407	None IPW  A 601 (-4.2A) IPW  A 601 (-3.5A) IPW  A 601 (-4.5A) IPW  A 601 ( 3.8A) None IPW  A 601 (-4.5A) None	0.53A	26.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	8 / 11	LEU A 593 VAL A 601 ALA A 617 MET A 674 GLY A 677 ASN A 728 ALA A 740 ASP A 741	7AE  A1000 ( 3.9A) 7AE  A1000 ( 4.9A) 7AE  A1000 (-3.3A) None 7AE  A1000 ( 3.7A) 7AE  A1000 (-4.7A) 7AE  A1000 ( 3.7A) 7AE  A1000 (-4.4A)	0.54A	38.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5tvt	MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (Homo sapiens)	8 / 11	GLY A  20 VAL A  25 ALA A  38 TYR A  88 GLY A  92 ASN A 137 LEU A 139 ASP A 150	7LV  A 401 ( 3.9A) 7LV  A 401 ( 4.6A) 7LV  A 401 (-3.4A) 7LV  A 401 (-4.6A) None None 7LV  A 401 (-4.9A) 7LV  A 401 (-4.2A)	0.73A	26.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	8 / 11	LEU A 542 VAL A 550 ALA A 565 MET A 623 GLY A 626 ASN A 677 ALA A 689 ASP A 690	7YS  A9001 (-4.1A) 7YS  A9001 (-4.2A) 7YS  A9001 (-3.3A) 7YS  A9001 (-4.7A) 7YS  A9001 (-3.4A) None 7YS  A9001 (-3.4A) None	0.67A	37.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5u7q	RHO-ASSOCIATED PROTEIN KINASE 2 (Homo sapiens)	10 / 11	GLY A 101 VAL A 106 ALA A 119 TYR A 171 MET A 172 GLY A 175 ASN A 219 LEU A 221 ALA A 231 ASP A 232	None	0.52A	24.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5uuu	BETA-ADRENERGIC RECEPTOR KINASE 1 (Homo sapiens)	8 / 11	GLY A 200 VAL A 205 ALA A 218 MET A 274 GLY A 277 ASN A 322 LEU A 324 ASP A 335	QRW  A 601 (-3.6A) QRW  A 601 (-4.7A) QRW  A 601 (-3.4A) MES  A 604 (-3.9A) None None None QRW  A 601 (-3.7A)	0.68A	21.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5w5j	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2 (Homo sapiens)	9 / 11	LEU A  24 VAL A  32 ALA A  45 TYR A  97 MET A  98 GLY A 101 ASN A 151 LEU A 153 ALA A 163	9WS  A 401 ( 4.2A) 9WS  A 401 ( 4.6A) 9WS  A 401 (-3.3A) None None 9WS  A 401 ( 4.3A) None 9WS  A 401 (-4.6A) 9WS  A 401 ( 4.0A)	0.57A	28.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	6ao5	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	9 / 11	LEU A  33 GLY A  36 VAL A  41 ALA A  54 TYR A 101 GLY A 105 ASN A 151 LEU A 153 ALA A 163	ANP  A 501 ( 3.8A) None ANP  A 501 (-4.4A) ANP  A 501 ( 3.7A) ANP  A 501 ( 4.2A) ANP  A 501 ( 4.0A) ANP  A 501 ( 2.6A) ANP  A 501 (-4.6A) None	1.07A	23.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	6ccf	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 1 (Homo sapiens)	8 / 11	GLY A 137 VAL A 142 ALA A 155 GLY A 236 ASN A 280 LEU A 282 ALA A 292 ASP A 293	None H1N  A 501 (-4.4A) H1N  A 501 (-3.4A) H1N  A 501 (-3.6A) H1N  A 501 (-4.5A) H1N  A 501 (-4.8A) H1N  A 501 ( 3.9A) H1N  A 501 (-3.5A)	0.51A	14.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	6f3d	INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (Homo sapiens)	9 / 11	GLY A 195 VAL A 200 ALA A 211 TYR A 264 MET A 265 GLY A 268 ASN A 316 LEU A 318 ASP A 329	None CJT  A 502 ( 4.8A) CJT  A 502 (-3.4A) CJT  A 502 (-4.5A) CJT  A 502 (-4.9A) CJT  A 502 ( 4.3A) None CJT  A 502 (-4.7A) CJT  A 502 ( 4.0A)	0.48A	13.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 9	LEU A 616 VAL A 624 ALA A 642 TYR A 693 GLY A 697 LEU A 818 ASP A 829	None	0.93A	36.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	6 / 9	LEU A  78 VAL A  86 ALA A  99 MET A 150 GLY A 153 LEU A 201	ATP  A 535 (-3.9A) ATP  A 535 (-4.1A) ATP  A 535 (-3.6A) None ATP  A 535 ( 4.7A) ATP  A 535 (-4.8A)	0.54A	26.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	6 / 9	LEU A 595 VAL A 603 ALA A 621 TYR A 672 GLY A 676 LEU A 799	STI  A   3 ( 3.8A) STI  A   3 ( 4.6A) STI  A   3 (-3.5A) STI  A   3 ( 4.0A) STI  A   3 ( 3.8A) STI  A   3 (-4.4A)	0.56A	35.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	6 / 9	LEU A 595 VAL A 603 ALA A 621 TYR A 672 LEU A 799 ASP A 810	STI  A   3 ( 3.8A) STI  A   3 ( 4.6A) STI  A   3 (-3.5A) STI  A   3 ( 4.0A) STI  A   3 (-4.4A) STI  A   3 (-3.9A)	0.74A	35.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1zlt	SERINE/THREONINE-PRO TEIN KINASE CHK1 (Homo sapiens)	6 / 9	LEU A  15 VAL A  23 ALA A  36 TYR A  86 GLY A  90 LEU A 137	HYM  A 400 (-4.2A) HYM  A 400 (-4.3A) HYM  A 400 (-3.5A) HYM  A 400 (-4.7A) None HYM  A 400 (-4.5A)	0.63A	26.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	6 / 9	ALA X  37 TYR X  84 MET X  85 GLY X  88 LEU X 137 ASP X 148	STU  X 902 (-3.1A) STU  X 902 (-4.6A) None STU  X 902 (-3.5A) STU  X 902 (-4.4A) STU  X 902 (-3.6A)	0.68A	84.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	7 / 9	LEU X  17 VAL X  25 ALA X  37 TYR X  84 MET X  85 GLY X  88 LEU X 137	STU  X 902 (-3.8A) STU  X 902 ( 4.8A) STU  X 902 (-3.1A) STU  X 902 (-4.6A) None STU  X 902 (-3.5A) STU  X 902 (-4.4A)	0.43A	84.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	6 / 9	LEU A 273 TYR A 340 MET A 341 GLY A 344 LEU A 393 ASP A 404	H8H  A 534 (-3.8A) H8H  A 534 (-4.3A) None H8H  A 534 (-3.3A) H8H  A 534 (-4.5A) H8H  A 534 (-4.2A)	0.76A	52.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	7 / 9	LEU A 273 VAL A 281 ALA A 293 TYR A 340 MET A 341 GLY A 344 LEU A 393	H8H  A 534 (-3.8A) H8H  A 534 (-4.4A) H8H  A 534 (-3.2A) H8H  A 534 (-4.3A) None H8H  A 534 (-3.3A) H8H  A 534 (-4.5A)	0.24A	52.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	6 / 9	LEU A 273 VAL A 281 ALA A 293 MET A 341 GLY A 344 LEU A 393	QUE  A   1 (-3.9A) QUE  A   1 ( 4.8A) QUE  A   1 (-3.5A) None QUE  A   1 (-3.0A) QUE  A   1 (-4.4A)	0.52A	51.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	7 / 9	LEU A 251 VAL A 259 ALA A 271 MET A 319 GLY A 322 LEU A 371 ASP A 382	1BM  A 499 ( 3.7A) 1BM  A 499 ( 4.8A) 1BM  A 499 (-3.6A) None 1BM  A 499 (-3.5A) 1BM  A 499 (-4.4A) 1BM  A 499 (-4.4A)	0.49A	67.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 9	LEU A 248 VAL A 256 ALA A 269 MET A 318 GLY A 321 LEU A 370	GIN  A 600 ( 4.6A) GIN  A 600 ( 4.7A) GIN  A 600 (-3.1A) None None GIN  A 600 (-4.7A)	0.49A	48.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	8 / 9	LEU A 251 VAL A 259 ALA A 271 TYR A 318 MET A 319 GLY A 322 LEU A 371 ASP A 382	None None 1N8  A 501 ( 3.4A) 1N8  A 501 ( 3.7A) 1N8  A 501 ( 4.4A) 1N8  A 501 ( 3.5A) 1N8  A 501 ( 4.3A) 1N8  A 501 ( 3.3A)	0.87A	67.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	7 / 9	LEU A 588 VAL A 596 ALA A 614 TYR A 665 GLY A 669 LEU A 785 ASP A 796	None	0.71A	34.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2psq	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	6 / 9	LEU A 487 VAL A 495 ALA A 515 TYR A 566 GLY A 570 LEU A 633	None	0.53A	32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2qob	EPHRIN RECEPTOR (Homo sapiens)	6 / 9	VAL A 635 ALA A 651 MET A 702 GLY A 705 LEU A 753 ASP A 764	BME  A   1 (-4.9A) PTR  A 701 ( 4.7A) PTR  A 701 ( 3.5A) None None None	0.36A	39.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2r2p	EPHRIN TYPE-A RECEPTOR 5 (Homo sapiens)	7 / 9	VAL A 689 ALA A 705 TYR A 755 MET A 756 GLY A 759 LEU A 807 ASP A 818	None	0.44A	43.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	6 / 9	LEU A 724 VAL A 732 ALA A 749 MET A 799 GLY A 802 LEU A 850	GW7  A   1 ( 4.2A) GW7  A   1 ( 4.8A) GW7  A   1 (-3.3A) None GW7  A   1 (-3.6A) GW7  A   1 (-4.2A)	0.53A	39.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2v55	RHO-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	6 / 9	VAL A  90 ALA A 103 TYR A 155 MET A 156 GLY A 159 LEU A 205	None ANP  A1480 ( 3.9A) ANP  A1480 ( 4.9A) None None ANP  A1480 ( 4.7A)	0.72A	23.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2xk9	CHECKPOINT KINASE 2 (Homo sapiens)	7 / 9	LEU A 226 VAL A 234 ALA A 247 MET A 304 GLY A 307 LEU A 354 ASP A 368	XK9  A1511 (-3.8A) XK9  A1511 (-4.8A) XK9  A1511 ( 4.1A) None XK9  A1511 ( 3.7A) XK9  A1511 (-4.6A) XK9  A1511 (-3.6A)	0.79A	28.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3b2t	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	6 / 9	LEU A 487 VAL A 495 ALA A 515 TYR A 566 GLY A 570 LEU A 633	M33  A1996 (-4.0A) M33  A1996 ( 4.7A) M33  A1996 (-3.3A) M33  A1996 ( 4.7A) M33  A1996 ( 4.8A) M33  A1996 (-4.5A)	0.50A	36.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3c4f	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	6 / 9	LEU A 484 VAL A 492 ALA A 512 TYR A 563 GLY A 567 LEU A 630	C4F  A   1 ( 3.9A) None C4F  A   1 (-3.3A) None None C4F  A   1 (-4.6A)	0.73A	36.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	6 / 9	ALA A 220 TYR A 268 MET A 269 GLY A 272 LEU A 321 ASP A 332	None	0.63A	42.01
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	6 / 9	VAL A 209 ALA A 220 TYR A 268 MET A 269 GLY A 272 LEU A 321	None	0.42A	42.01
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3hng	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	7 / 9	LEU A 833 VAL A 841 ALA A 859 TYR A 911 GLY A 915 LEU A1029 ASP A1040	8ST  A2001 ( 4.7A) 8ST  A2001 ( 4.6A) 8ST  A2001 ( 3.8A) 8ST  A2001 (-4.9A) None None None	0.87A	31.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3iec	SERINE/THREONINE-PRO TEIN KINASE MARK2 (Homo sapiens)	6 / 9	VAL A  67 ALA A  80 TYR A 131 GLY A 135 LEU A 182 ASP A 193	None	0.75A	27.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3kul	EPHRIN TYPE-A RECEPTOR 8 (Homo sapiens)	6 / 9	VAL A 649 ALA A 665 TYR A 715 MET A 716 GLY A 719 LEU A 767	None None GOL  A 403 (-4.1A) None GOL  A 403 (-3.4A) None	0.51A	38.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3lm5	SERINE/THREONINE-PRO TEIN KINASE 17B (Homo sapiens)	6 / 9	LEU A  39 VAL A  47 ALA A  60 TYR A 112 GLY A 116 LEU A 165	QUE  A   1 ( 3.8A) QUE  A   1 ( 4.6A) QUE  A   1 (-3.2A) QUE  A   1 (-4.9A) None None	0.75A	27.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3mvj	CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA (Homo sapiens)	6 / 9	LEU A  49 VAL A  57 ALA A  70 TYR A 122 GLY A 126 LEU A 173	XFE  A 351 (-4.2A) XFE  A 351 ( 4.5A) XFE  A 351 (-3.2A) None None XFE  A 351 (-4.6A)	0.65A	23.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3nuu	PKB-LIKE (Homo sapiens)	7 / 9	LEU A  88 VAL A  96 ALA A 109 TYR A 161 GLY A 165 LEU A 212 ASP A 223	JOZ  A 361 (-4.1A) JOZ  A 361 ( 4.7A) JOZ  A 361 (-3.4A) None None None SO4  A   5 ( 4.5A)	0.87A	26.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3nyo	G PROTEIN-COUPLED RECEPTOR KINASE 6 (Homo sapiens)	6 / 9	LEU A 192 VAL A 200 ALA A 213 MET A 266 GLY A 269 LEU A 318	AMP  A 577 ( 4.3A) AMP  A 577 (-4.3A) AMP  A 577 (-3.4A) None None AMP  A 577 (-4.8A)	0.36A	22.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	6 / 9	LEU A 726 VAL A 734 ALA A 751 MET A 801 GLY A 804 LEU A 852	03Q  A   1 (-3.8A) 03Q  A   1 (-4.5A) 03Q  A   1 (-3.1A) None 03Q  A   1 ( 3.9A) 03Q  A   1 (-4.4A)	0.47A	36.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3sxs	CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX (Homo sapiens)	6 / 9	LEU A 423 VAL A 431 ALA A 443 TYR A 491 GLY A 495 LEU A 543	PP2  A   1 (-4.1A) PP2  A   1 (-4.5A) PP2  A   1 (-3.2A) PP2  A   1 ( 4.9A) PP2  A   1 ( 4.2A) PP2  A   1 (-4.6A)	0.53A	43.01
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3tt0	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	6 / 9	LEU A 484 VAL A 492 ALA A 512 TYR A 563 GLY A 567 LEU A 630	07J  A   1 ( 4.3A) 07J  A   1 (-4.0A) 07J  A   1 (-3.5A) 07J  A   1 (-4.7A) 07J  A   1 (-3.7A) 07J  A   1 ( 4.4A)	0.74A	33.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3v5q	NT-3 GROWTH FACTOR RECEPTOR (Homo sapiens)	7 / 9	LEU A 544 VAL A 552 ALA A 570 TYR A 619 MET A 620 GLY A 623 LEU A 686	0F4  A 902 ( 4.2A) None 0F4  A 902 (-3.2A) 0F4  A 902 (-4.2A) None 0F4  A 902 (-3.4A) 0F4  A 902 (-4.5A)	0.53A	34.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3w18	AURORA KINASE A (Homo sapiens)	6 / 9	LEU A 139 VAL A 147 ALA A 160 TYR A 212 GLY A 216 LEU A 263	N13  A 501 (-3.7A) N13  A 501 ( 4.7A) N13  A 501 ( 4.1A) N13  A 501 (-4.4A) N13  A 501 (-3.5A) N13  A 501 (-4.5A)	0.64A	24.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	6 / 9	LEU A  75 VAL A  83 ALA A  96 MET A 147 GLY A 150 LEU A 198	ANP  A 401 (-3.8A) ANP  A 401 ( 4.3A) ANP  A 401 (-3.2A) None ANP  A 401 ( 4.3A) ANP  A 401 (-4.8A)	0.51A	27.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	7 / 9	LEU A1951 VAL A1959 ALA A1978 MET A2029 GLY A2032 LEU A2086 ASP A2102	VGH  A3000 ( 4.4A) None VGH  A3000 (-3.4A) None VGH  A3000 (-3.5A) VGH  A3000 (-4.3A) None	0.61A	40.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4af3	AURORA KINASE B (Homo sapiens)	6 / 9	LEU A  83 VAL A  91 ALA A 104 TYR A 156 GLY A 160 LEU A 207	VX6  A 500 (-3.8A) VX6  A 500 ( 4.8A) VX6  A 500 (-3.4A) VX6  A 500 (-4.2A) VX6  A 500 (-3.3A) VX6  A 500 (-4.6A)	0.43A	23.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4at3	BDNF/NT-3 GROWTH FACTORS RECEPTOR (Homo sapiens)	8 / 9	LEU A 560 VAL A 568 ALA A 586 TYR A 635 MET A 636 GLY A 639 LEU A 699 ASP A 710	LTI  A1839 ( 4.2A) None LTI  A1839 (-3.3A) LTI  A1839 (-4.7A) None LTI  A1839 (-3.4A) LTI  A1839 (-4.2A) None	0.61A	33.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4aw5	EPHRIN TYPE-B RECEPTOR 4 (Homo sapiens)	6 / 9	VAL A 105 ALA A 121 MET A 172 GLY A 175 LEU A 223 ASP A 234	30K  A1365 ( 4.6A) 30K  A1365 (-3.2A) None 30K  A1365 (-3.5A) 30K  A1365 (-4.5A) 30K  A1365 (-3.3A)	0.58A	42.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4ckr	EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1 (Homo sapiens)	7 / 9	LEU A 616 VAL A 624 ALA A 653 TYR A 703 MET A 704 LEU A 773 ASP A 784	None DI1  A1000 (-4.8A) DI1  A1000 (-3.6A) DI1  A1000 (-4.0A) None DI1  A1000 (-4.5A) DI1  A1000 (-4.1A)	0.90A	35.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4crs	SERINE/THREONINE-PRO TEIN KINASE N2 (Homo sapiens)	6 / 9	LEU A 663 VAL A 671 ALA A 684 TYR A 739 GLY A 743 LEU A 789	AGS  A1985 (-4.2A) AGS  A1985 (-4.6A) AGS  A1985 (-3.5A) None None AGS  A1985 (-4.8A)	0.58A	24.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4f0i	HIGH AFFINITY NERVE GROWTH FACTOR RECEPTOR (Homo sapiens)	7 / 9	LEU A 515 VAL A 523 ALA A 541 TYR A 590 MET A 591 GLY A 594 LEU A 656	None	0.50A	33.98
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4fod	ALK TYROSINE KINASE RECEPTOR (Homo sapiens)	7 / 9	LEU A1122 VAL A1130 ALA A1148 MET A1199 GLY A1202 LEU A1256 ASP A1270	0UV  A1501 (-3.8A) 0UV  A1501 (-4.5A) 0UV  A1501 (-3.4A) None 0UV  A1501 (-3.6A) 0UV  A1501 (-4.6A) 0UV  A1501 ( 4.2A)	0.59A	33.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4hvi	TYROSINE-PROTEIN KINASE JAK3 (Homo sapiens)	6 / 9	LEU A 828 VAL A 836 ALA A 853 TYR A 904 GLY A 908 LEU A 956	19S  A1201 (-3.9A) 19S  A1201 (-4.4A) 19S  A1201 (-3.3A) 19S  A1201 (-4.7A) 19S  A1201 ( 3.8A) 19S  A1201 (-4.5A)	0.50A	33.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4id7	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 9	LEU A 132 VAL A 140 ALA A 156 GLY A 211 LEU A 259 ASP A 270	1G0  A 401 ( 4.5A) 1G0  A 401 (-4.4A) 1G0  A 401 (-3.6A) 1G0  A 401 ( 4.5A) 1G0  A 401 (-4.6A) None	0.62A	39.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4jxf	SERINE/THREONINE-PRO TEIN KINASE PLK4 (Homo sapiens)	6 / 9	LEU A  18 VAL A  26 ALA A  39 GLY A  95 LEU A 143 ASP A 154	631  A 301 (-3.4A) 631  A 301 (-4.6A) 631  A 301 (-3.3A) 631  A 301 ( 3.7A) 631  A 301 (-4.0A) EDO  A 302 (-3.7A)	0.59A	29.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4k11	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	7 / 9	LEU A 273 VAL A 281 ALA A 293 TYR A 340 MET A 341 GLY A 344 LEU A 393	0J9  A 601 (-4.0A) 0J9  A 601 (-4.4A) 0J9  A 601 (-3.3A) 0J9  A 601 ( 4.7A) None 0J9  A 601 ( 4.1A) 0J9  A 601 (-4.5A)	0.45A	94.59
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	6 / 9	LEU A 478 ALA A 506 TYR A 557 GLY A 561 LEU A 624 ASP A 635	ACP  A 801 (-3.8A) ACP  A 801 (-3.3A) None ACP  A 801 ( 4.6A) ACP  A 801 (-4.4A) MG  A 802 ( 3.0A)	0.68A	35.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	6 / 9	LEU A 478 VAL A 486 ALA A 506 TYR A 557 GLY A 561 LEU A 624	ACP  A 801 (-3.8A) ACP  A 801 (-4.2A) ACP  A 801 (-3.3A) None ACP  A 801 ( 4.6A) ACP  A 801 (-4.4A)	0.65A	35.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4oli	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	6 / 9	LEU A 903 VAL A 911 ALA A 928 TYR A 980 GLY A 984 LEU A1030	2TT  A1202 (-3.5A) 2TT  A1202 (-4.5A) 2TT  A1202 ( 3.9A) 2TT  A1202 (-4.6A) 2TT  A1202 (-3.4A) 2TT  A1202 (-4.4A)	0.69A	20.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4otd	SERINE/THREONINE-PRO TEIN KINASE N1 (Homo sapiens)	6 / 9	LEU A 627 VAL A 635 ALA A 648 TYR A 703 GLY A 707 LEU A 753	None	0.50A	26.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4p2k	EPHRIN TYPE-A RECEPTOR 2 (Homo sapiens)	7 / 9	VAL A 627 ALA A 644 TYR A 694 MET A 695 GLY A 698 LEU A 746 ASP A 757	None	0.51A	43.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4rew	5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-1 (Homo sapiens)	6 / 9	LEU A  24 VAL A  32 ALA A  45 TYR A  97 GLY A 101 LEU A 148	STU  A 601 (-3.7A) STU  A 601 ( 4.8A) STU  A 601 (-3.2A) STU  A 601 (-4.4A) STU  A 601 ( 3.8A) STU  A 601 (-4.2A)	0.77A	21.34
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4rt7	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	7 / 9	LEU A 616 VAL A 624 ALA A 642 TYR A 693 GLY A 697 LEU A 818 ASP A 829	P30  A1001 (-3.8A) None P30  A1001 (-3.4A) P30  A1001 (-4.1A) P30  A1001 (-3.4A) P30  A1001 (-4.6A) None	0.71A	32.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4wb7	DNAJ HOMOLOG SUBFAMILY B MEMBER 1,CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA (Homo sapiens)	6 / 9	LEU A 104 VAL A 112 ALA A 125 TYR A 177 GLY A 181 LEU A 228	ATP  A 501 ( 4.3A) ATP  A 501 (-4.0A) ATP  A 501 (-3.4A) None None ATP  A 501 (-4.5A)	0.66A	23.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	6 / 9	LEU B 267 VAL B 275 ALA B 288 MET B 337 GLY B 340 LEU B 389	1N1  B 601 (-3.7A) 1N1  B 601 ( 4.9A) 1N1  B 601 (-3.5A) None 1N1  B 601 (-3.5A) 1N1  B 601 (-4.3A)	0.27A	36.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4xuf	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	7 / 9	LEU A 616 VAL A 624 ALA A 642 TYR A 693 GLY A 697 LEU A 818 ASP A 829	P30  A1001 (-4.0A) P30  A1001 ( 4.8A) P30  A1001 (-3.5A) P30  A1001 ( 4.4A) P30  A1001 (-3.5A) P30  A1001 (-4.3A) None	0.72A	38.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4yhj	G PROTEIN-COUPLED RECEPTOR KINASE 4 (Homo sapiens)	6 / 9	LEU A 193 VAL A 201 ALA A 214 MET A 267 LEU A 319 ASP A 330	AN2  A 601 ( 4.2A) AN2  A 601 (-4.0A) AN2  A 601 (-3.6A) None None AN2  A 601 (-3.0A)	0.68A	20.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5a46	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B (Homo sapiens)	6 / 9	LEU A 484 VAL A 492 ALA A 512 TYR A 563 GLY A 567 LEU A 630	38O  A1769 (-3.2A) 38O  A1769 (-4.5A) 38O  A1769 (-3.6A) 38O  A1769 (-4.2A) 38O  A1769 (-3.4A) 38O  A1769 (-4.6A)	0.58A	32.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5f1z	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	6 / 9	LEU A 903 VAL A 911 ALA A 928 TYR A 980 GLY A 984 LEU A1030	5U3  A1200 (-3.8A) 5U3  A1200 ( 4.4A) 5U3  A1200 (-3.5A) 5U3  A1200 (-4.5A) 5U3  A1200 (-3.2A) 5U3  A1200 (-4.4A)	0.45A	34.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5fm2	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET (Homo sapiens)	6 / 9	LEU A 730 VAL A 738 ALA A 756 TYR A 806 GLY A 810 LEU A 881	PP1  A2012 (-4.6A) PP1  A2012 (-4.4A) PP1  A2012 (-3.2A) None PTR  A 809 (-2.4A) PP1  A2012 (-4.6A)	0.52A	31.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	6 / 9	LEU A 599 VAL A 607 ALA A 625 TYR A 676 GLY A 680 LEU A 825	748  A1001 (-3.8A) 748  A1001 ( 4.7A) 748  A1001 (-3.7A) 748  A1001 (-4.0A) 748  A1001 ( 4.0A) 748  A1001 (-4.3A)	0.52A	34.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	6 / 9	LEU A 599 VAL A 607 ALA A 625 TYR A 676 LEU A 825 ASP A 836	748  A1001 (-3.8A) 748  A1001 ( 4.7A) 748  A1001 (-3.7A) 748  A1001 (-4.0A) 748  A1001 (-4.3A) 748  A1001 (-4.8A)	0.79A	34.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5hor	HEPATOCYTE GROWTH FACTOR RECEPTOR (Homo sapiens)	6 / 9	VAL A1092 ALA A1108 TYR A1159 MET A1160 GLY A1163 ASP A1222	63K  A1401 (-4.9A) 63K  A1401 (-3.5A) 63K  A1401 (-3.5A) None 63K  A1401 (-3.6A) None	0.58A	36.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5i3o	BMP-2-INDUCIBLE PROTEIN KINASE (Homo sapiens)	6 / 9	LEU A  57 VAL A  65 ALA A  77 TYR A 132 GLY A 136 LEU A 187	IDV  A 401 (-3.8A) IDV  A 401 (-4.6A) IDV  A 401 (-3.6A) IDV  A 401 (-3.5A) IDV  A 401 (-3.4A) IDV  A 401 (-4.4A)	0.55A	25.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	6 / 9	LEU A 718 VAL A 726 ALA A 743 MET A 793 GLY A 796 LEU A 844	6HJ  A1101 ( 4.6A) 6HJ  A1101 ( 4.7A) 6HJ  A1101 (-3.1A) None 6HJ  A1101 ( 4.5A) 6HJ  A1101 ( 4.8A)	0.39A	33.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	6 / 9	LEU A 593 VAL A 601 ALA A 617 MET A 674 GLY A 677 ASP A 741	7AE  A1000 ( 3.9A) 7AE  A1000 ( 4.9A) 7AE  A1000 (-3.3A) None 7AE  A1000 ( 3.7A) 7AE  A1000 (-4.4A)	0.71A	38.13
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	6 / 9	LEU A 542 VAL A 550 ALA A 565 MET A 623 GLY A 626 ASP A 690	7YS  A9001 (-4.1A) 7YS  A9001 (-4.2A) 7YS  A9001 (-3.3A) 7YS  A9001 (-4.7A) 7YS  A9001 (-3.4A) None	0.71A	37.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5u7q	RHO-ASSOCIATED PROTEIN KINASE 2 (Homo sapiens)	7 / 9	VAL A 106 ALA A 119 TYR A 171 MET A 172 GLY A 175 LEU A 221 ASP A 232	None	0.78A	24.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5w5j	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2 (Homo sapiens)	7 / 9	LEU A  24 VAL A  32 ALA A  45 TYR A  97 MET A  98 GLY A 101 LEU A 153	9WS  A 401 ( 4.2A) 9WS  A 401 ( 4.6A) 9WS  A 401 (-3.3A) None None 9WS  A 401 ( 4.3A) 9WS  A 401 (-4.6A)	0.59A	28.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	6ao5	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	6 / 9	LEU A  33 VAL A  41 ALA A  54 TYR A 101 GLY A 105 LEU A 153	ANP  A 501 ( 3.8A) ANP  A 501 (-4.4A) ANP  A 501 ( 3.7A) ANP  A 501 ( 4.2A) ANP  A 501 ( 4.0A) ANP  A 501 (-4.6A)	0.43A	23.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	6cz4	PROTEIN-TYROSINE KINASE 6 (Homo sapiens)	6 / 9	VAL A 205 ALA A 217 MET A 267 GLY A 270 LEU A 319 ASP A 330	FKY  A9001 ( 4.6A) FKY  A9001 (-3.3A) None FKY  A9001 (-3.3A) FKY  A9001 ( 4.9A) None	0.71A	16.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	6f3d	INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (Homo sapiens)	7 / 9	VAL A 200 ALA A 211 TYR A 264 MET A 265 GLY A 268 LEU A 318 ASP A 329	CJT  A 502 ( 4.8A) CJT  A 502 (-3.4A) CJT  A 502 (-4.5A) CJT  A 502 (-4.9A) CJT  A 502 ( 4.3A) CJT  A 502 (-4.7A) CJT  A 502 ( 4.0A)	0.69A	13.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	6fek	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET (Homo sapiens)	6 / 9	LEU A 730 VAL A 738 ALA A 756 TYR A 806 GLY A 810 LEU A 881	ADN  A1104 ( 4.0A) ADN  A1104 (-4.4A) ADN  A1104 (-3.4A) ADN  A1104 ( 4.1A) ADN  A1104 ( 3.8A) ADN  A1104 (-4.3A)	0.46A	13.75